drugset / Trial / NCT01933672
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
RandomizedCrossoverTriple-blindBasic science
Summary
Study B1621019 will assess efficacy and safety of two different dosing regimens of an investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients with type 2 diabetes
Timeline
- Start
- 2013-10
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NERIGLIATIN | Small molecule | 100 mg | — |
| Subject | NERIGLIATIN | Small molecule | 150 mg | — |
| Subject | NERIGLIATIN | Small molecule | 300 mg | — |
| Comparator | Sitagliptin | Small molecule | 100 mg | — |